Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation

Journal of the American College of Cardiology

Volumn 37, Issue 3, 2001, Pages 691-704

  Klein, Allan L ^a   Murray, R Daniel ^a   Grimm, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART PERFORMANCE; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; TECHNIQUE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 0035282120     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01178-5     Document Type: Article

References (149)

1. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation?
2. Antithrombotic therapy in atrial fibrillation
3. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
4. Cardioversion guided by transesophageal echocardiography: The ACUTE pilot study - A randomized, controlled trial
5. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanti-coagulated cardioversion from atrial fibrillation and flutter: An analysis of pooled trials
6. Management of atrial fibrillation: Simplicity surrounded by controversy
7. Perspectives and controversies in atrial fibrillation
8. Multiplane transesophageal echocardiography and stroke
9. Transesophageal echocardiography-guided cardioversion: Going for broke?
10. Should TEE be done routinely before cardioversion
11. All patients with new-onset atrial fibrillation should undergo TEE prior to cardioversion
12. TEE-guided cardioversion should be the routine approach; protagonist/antagonist
13. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association
14. ACC/AHA guidelines for the clinical application of echocardiography: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography)
15. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (ACUTE multicenter study)
16. Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) multicenter study: Eight week clinical outcomes
17. Electrocardiographic findings among the adult population of a total natural community - Tecumseh, Michigan
18. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications
19. Coronary heart disease and atrial fibrillation: The Framingham study
20. Management of atrial fibrillation in adults: Prevention of thrombo-embolism and symptomatic treatment
21. Epidemiologic features of chronic atrial fibrillation: The Framingham study
22. Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy
23. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
24. Prevention of stroke
25. Impact of atrial fibrillation on mortality, stroke and medical costs
26. Antithrombotic therapy in atrial fibrillation
27. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
28. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
29. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
30. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
31. Preventing stroke in patients with atrial fibrillation
32. A prospective study of left atrial spontaneous echo contrast and thrombus in 100 consecutive patients referred for balloon dilation of the mitral valve
33. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients
34. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study
35. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation: A 2-year follow-up
36. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy
37. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
38. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats
39. Stroke Prevention in Atrial Fibrillation (SPAF) study: Final results
40. Newer developments in the management of atrial fibrillation
41. New method for terminating cardiac arrhythmias
42. Factors influencing conversion of chronic atrial fibrillation with specific reference to serum quinidine concentration
43. The management of chronic atrial fibrillation
44. "Cardioversion" of atrial fibrillation: A report on the treatment of 65 episodes in 50 patients
45. Hemodynamic effects after reversion from atrial fibrillation to sinus rhythm by precordial shock
46. Atrial fibrillation: Anticoagulation and quinidinization
47. Quinidine therapy of chronic auricular fibrillation: The occurrence and mechanism of syncope
48. Experience with cardioversion of atrial fibrillation and flutter
49. Further experience of electrical conversion of atrial fibrillation to sinus rhythm: Analysis of 100 patients
50. Management of patients with atrial fibrillation
51. Electrical conversion of atrial fibrillation: Immediate and long-term results and selection of patients
52. Conversion of atrial arrhythmias with DC shock: Primary results and a follow-up investigation
53. Direct current cardioversion of atrial fibrillation
54. Immediate and long-term results of electrical conversion of arrhythmias
55. Electrical reversion of cardiac arrhythmias
56. Haemodynamic studies before and after electrical conversion of atrial fibrillation and flutter to sinus rhythm
57. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine
58. Long-term results of DC reversion of atrial fibrillation
59. Direct current conversion of atrial fibrillation: Long-term results
60. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation
61. Prognosis of atrial arrhythmias treated by electrical counter shock therapy: A three-year follow-up
62. Relation between echocardiographically determined left atrial size and atrial fibrillation
63. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation
64. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter
65. Cardioversion of atrial fibrillation in the elderly
66. Cardioversion related stroke rates in atrial fibrillation and atrial flutter
67. A review of direct current cardioversions for atrial arrhythmia
68. Antithrombotic therapy in atrial fibrillation: Third ACCP Conference on Antithrombotic Therapy
69. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation
70. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation
71. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm
72. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation
73. Anticoagulation for cardioversion of atrial fibrillation
74. A 7-year analysis of haemorrhage in patients on long term anticoagulant treatment
75. Canadian Atrial Fibrillation Anticoagulation (CAFA) study
76. Hemorrhagic complications of long-term anticoagulant therapy
77. Hemorrhagic complications of anticoagulant treatment
78. Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation
79. The role of transesophageal echocardiography in the detection of left atrial thrombi
80. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: Identification of a subgroup of patients at increased embolic risk
81. Accuracy of transesophageal echocardiography for identifying left atrial thrombi
82. Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulation
83. Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus
84. Diagnosis of left atrial appendage thrombi by transesophageal echocardiography: Clinical implications and follow-up
85. Features of patients with severe mitral stenosis with respect to atrial rhythm: Atrial fibrillation in predominant and tight mitral stenosis
86. Exclusion of atrial thrombus by transesophageal echocardiography
87. Diagnostic accuracy of left atrial appendage thrombi by transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations
88. Accuracy of biplane transesophageal echocardiography in detecting left atrial thrombus
89. Detection of left atrial thrombi by echocardiography
90. Smoke-like echo in the left atrial cavity in mitral valve disease: Its features and significance
91. Dynamic intracavitary left atrial echoes in mitral stenosis
92. Left atrial spontaneous contrast in mitral vane disease: An indicator for increased thromboembolic risk
93. Detection of spontaneous echocardiographic contrast within the left atrium by transesophageal echocardiography: Spontaneous echocardiographic contrast
94. Left atrial spontaneous echo contrast: A clinical and echocardiographic analysis
95. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation
96. Safety of transesophageal echocardiography: A multicenter survey of 10,419 examinations
97. Transesophageal echocardiography
98. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation
99. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation
100. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: The Stroke Prevention in Atrial Fibrillation III study
101. Cardioversion in atrial fibrillation: Indications, thromboembolic prophylaxis, and role of transesophageal echocardiography
102. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation
103. Usefulness of transesophageal echocardiography to screen for left atrial thrombus before elective cardioversion for atrial fibrillation
104. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography
105. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for "atrial stunning" as a mechanism of thromboembolic complications
106. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation
107. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography
108. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation
109. Left atrial chamber and appendage function after internal atrial defibrillation: A prospective and serial transesophageal echocardiographic study
110. Left atrial mechanical function after brief duration atrial fibrillation
111. Left atrial appendage "stunning" following electrical cardioversion of atrial flutter: An attenuated response as compared to atrial fibrillation as a mechanism for a lower susceptibility to thromboembolic events
112. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study
113. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study
114. Transesophageal echocardiography facilitated cardioversion from atrial fibrillation: Short-term safety and implications regarding maintenance of sinus rhythm
115. TEE-guided anticoagulation in patients undergoing electrical cardioversion of atrial fibrillation: Results from the ACUTE Registry
116. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation
117. Results from late-breaking clinical trial sessions at ACCIS 2000 and ACC 2000
118. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: A decision analytic model for patients admitted to the hospital with atrial fibrillation
119. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: Should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis
120. Cardioversion of nonrheumatic atrial fibrillation: Reduced thromboembolic complications with four weeks of precardioversion anticoagulation are related to atrial thrombus resolution
121. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation
122. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study
123. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram
124. Transesophageal echocardiographic prediction of initially successful electrical cardioversion of isolated atrial fibrillation: Effects of left atrial appendage function
125. Echocardiographic parameters for predicting maintenance of sinus rhythm after internal atrial defibrillation
126. Is left atrial appendage flow a predictor for outcome of cardioversion of nonvalvular atrial fibrillation? A transthoracic and transesophageal echocardiographic study
127. Transesophageal echocardiographic predictors for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation
128. Echocardiographic assessment of the left atrial appendage
129. Is it safe to cardiovert atrial fibrillation without anticoagulation if the transesophageal echocardiogram is normal?
130. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
131. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy
132. Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: A reanalysis with recently acquired data
133. Chronic atrial fibrillation: Success of serial cardioversion therapy and safety of oral anticoagulation
134. Early recurrence of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria?
135. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention
136. Anatomy of the normal left atrial appendage: A quantitative study of age-related changes in 500 autopsy hearts - Implications for echocardiographic examination
137. Left atrial appendage "sludge" in atrial fibrillation patients undergoing TEE screening for cardioversion: The ACUTE registry
138. Guidelines for physician training in transesophageal echocardiography: Recommendations of the American Society of Echocardiography Committee for Physician Training in Echocardiography
139. Guidelines for training in adult cardiovascular medicine. Core cardiology training symposium. Task force 4: Training in echocardiography
140. National use of the transesophageal echocardiographic-guided approach to cardioversion for patients in atrial fibrillation
141. Emerging role of echocardiography in the evaluation of patients with atrial fibrillation into the new millennium
142. Antithrombotic therapy in nonrheumatic/nonvalvular atrial fibrillation
143. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation
144. Transesophageal echocardiography and atrial fibrillation: Added value or expensive toy?
145. Transesophageal echocardiography-guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: The ACUTE II pilot study
146. Potential clinical efficacy and cost benefit of a TEE-guided low molecular weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation
147. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter: Selection of a low-risk group for immediate cardioversion
148. Ibutilide
149. Dofetilide in patients with congestive heart failure and left ventricular dysfunction